Co-Diagnostics Inc. (NASDAQ:CODX) on Wednesday said CoSara Diagnostics Pvt. Ltd, its joint venture in India, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro instrument.
The molecular diagnostics company said the initiation of these clinical studies marks another critical milestone for the Co-Dx PCR platform, following the company’s previously announced shipment of PCR Pro instruments, mycobacterium tuberculosis (TB or MTB) test kits and proprietary sample preparation instruments to CoSara.
Read Next
News
EXCLUSIVE: Co-Diagnostics Reaches Regulatory Milestone for PCR Respiratory Test Platform
